KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $2.9 million.

  • Royalty Pharma's Change in Acquisitions & Divestments changed 0.0% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.9 million, marking a year-over-year increase of 32961.11%. This contributed to the annual value of $19.8 million for FY2024, which is 1887.99% down from last year.
  • As of Q3 2025, Royalty Pharma's Change in Acquisitions & Divestments stood at $2.9 million, which was down 0.0% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Change in Acquisitions & Divestments registered a high of $624.4 million during Q3 2021, and its lowest value of $1.4 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $64.6 million (2021), whereas its average is $153.3 million.
  • Per our database at Business Quant, Royalty Pharma's Change in Acquisitions & Divestments crashed by 9409.62% in 2024 and then soared by 77402.78% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Change in Acquisitions & Divestments stood at $104.7 million in 2021, then increased by 10.43% to $115.6 million in 2022, then plummeted by 78.91% to $24.4 million in 2023, then crashed by 48.4% to $12.6 million in 2024, then tumbled by 77.12% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q3 2025, $2.9 million for Q2 2025, and $12.6 million during Q1 2025.